AC Immune is offloading 6 million IPO shares, 32% more than originally planned, at the bottom end of its targeted $11 to $13 price range.

Daniel Soland has quit as CEO of uniQure "due to personal family reasons" 9 months after taking the job.

Teva has posted positive Phase III data for its involuntary twitch candidate deutetrabenazine as its gears up for a 2016 FDA filing--putting it a few months…

Gilead said in a brief update that it will be canning its combined Phase II/III test of its experimental GI med GS-5745 after finding that there was “…

Nitric oxide dermatology player Novan nabbed a nice share price pop on its first day of trading; after the first few hours it had gained 55%.

Eleven Bio is looking to come back to life after being on life support for much of 2016 with a merger deal combining it with Canadian company Viventia, who…

To any other private biotech, sinking $110 million into a custom-built manufacturing facility while its most advanced programs are in Phase II would be…

Mast was down by more than 80% premarket this morning on the news that its late-stage sickle cell disease candidate vepoloxamer (MST-188) failed to beat…

SV Life Sciences has joined with the VC wings of AbbVie and Merck KGaA to funnel $33.2 million into a DNA damage repair startup.